

# Manejo del dolor en osteoartritis

María Mercedes Comes, Agustín Martínez

AniCura Aitana Hospital Veterinario

## Bibliografía:

1. Rychel, J. K. (2010a). Diagnosis and treatment of osteoarthritis. *Topics in Companion Animal Medicine*, 25(1), 20–25. <https://doi.org/10.1053/j.tcam.2009.10.005>
2. Pye, C., Bruniges, N., Peffers, M., & Comerford, E. (2022). Advances in the pharmaceutical treatment options for canine osteoarthritis. *Journal of Small Animal Practice*, 63(10), 721–738. <https://doi.org/10.1111/jsap.13495>
3. Lascelles, B. D., Hansen, B. D., Roe, S., DePuy, V., et al., (2007). Evaluation of client-specific outcome measures and activity monitoring to measure pain relief in cats with osteoarthritis. *Journal of Veterinary Internal Medicine*, 21(3), 410.
4. O'Neill, D.G.; Church, D.B.; McGreevy, P.D.; Thomson, P.C.; Brodbelt, D.C. (2014) Prevalence of Disorders Recorded in Dogs Attending Primary-Care Veterinary Practices in England. *PLoS ONE*, 9, e90501.
5. Zapata, A.; Fernández-Parra, R. (2023) Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and Boswellia serrata. *Animals*, 13, 870. <https://doi.org/10.3390/ani13050870>
6. He, Y., Zhong, L.A., Peter, A., Ocasio, B.D., et al., (2020) Pathogenesis of Osteoarthritis: Risk Factors, Regulatory Pathways in Chondrocytes, and Experimental Models. *Biology*, 9, 194.
7. Summers, J.F.; O'Neill, D.G.; Church, D.; Collins, L.; et al., (2019). Health-Related Welfare Prioritisation of Canine Disorders Using Electronic Health Records in Primary Care Practice in the UK. *BMC Vet. Res.* 2019, 15, 163.
8. Cabezas Salamanca, M. Á., Castro Sousa, P., & Novoa Ojea, D. (2019). Guía Práctica Ortopédica Canina. *Scribd*. <https://es.scribd.com/document/620867113/Guia-Practica-Ortopedica-Canina>
9. Cachon, T., Frykman, O., Innes, J. F., Lascelles, B. D. X., et al., (2023). COAST Development Group's international consensus guidelines for the treatment of canine osteoarthritis. *Frontiers in veterinary science*, 10, 1137888. <https://doi.org/10.3389/fvets.2023.1137888>
10. Olcoz, M., Cabezas, M.Á., Rocca, G.D., Gómez de Segura, I.A., (2023) Translation to Spanish and linguistic validation of the Canine Brief Pain Inventory. *Front Vet Sci.* Jun 30;10:1203453. doi: 10.3389/fvets.2023.1203453. PMID: 37456964; PMCID: PMC10348357.
11. Harper, T. A. M. (2017). Conservative management of hip dysplasia. *The Veterinary Clinics of North America. Small Animal Practice*, 47(4), 807–821.

12. Budsberg SC. ( 1997) Outcome assessment in clinical trials involving medical management of osteoarthritis in small animals. *VetClin North Am Small Anim Pract* , Jul;27(4):815-23
13. Sanderson, R. O., Beata, C., Flipo, R. M., Genevois, J. P., Macias, C., Tacke, S., Vezzoni, A., & Innes, J. F. (2009). Systematic review of the management of canine osteoarthritis. *The Veterinary record*, 164(14), 418–424. <https://doi.org/10.1136/vr.164.14.418>
14. Monteiro, B.P. *et al.* (2022) '2022 WSAVA guidelines for the recognition, assessment and treatment of pain', *Journal of Small Animal Practice*, 64(4), pp. 177–254. doi:10.1111/jsap.13566.
15. National Office of Animal Health. (2021b). NOAH compendium, Datasheet for Galliprant (Elanco) tablets for dogs. <https://www.noahcompendium.co.uk/?id=-472523>. Accessed October 8, 2021
16. Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010). Clinical pharmacokinetics of therapeutic monoclonal antibodies. *Clinical Pharmacokinetics*, 49(8), 493–507. <https://doi.org/10.2165/11531280-000000000-00000>
17. Enomoto, M., Manthyh, PW., Murrel J, Innes JF., Lascelles, BDX., (2019) Anti-nerve growth factor monoclonar antibodies for the control of pain in dogs and cats. *Vet Rec.*;181 (1):23.
18. Oliviry, T., Bainbridge, G., ( 2015) Advances in veterinary medicine: therapeutic monoclonal antibodies for companion animals. *Clinican´s Brief*. Published March
19. Lascelles, B. D. X., Gaynor, J. S., Smith, E. S., et al. (2008) Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. *Journal of Veterinary Internal Medicine* 22, 53-59
20. Norkus, C., Rankin, D., Warner, M., KuKanich, B. (2015) Pharmacokinetics of oral amantadine in greyhound dogs. *J Vet Pharmacol Ther.* Jun;38(3):305-8. doi: 10.1111/jvp.12190. Epub 2014 Nov 27. PMID: 25427541.
21. Gruen ME, Lascelles BDX, Colleran E, Gottlieb A, Johnson J, Lotsikas P, et al. (2022) 2022 AAHA pain management guidelines for dogs and cats. *J Am Anim Hosp Assoc* [Internet] ;58(2):55–76. Disponible en: <http://dx.doi.org/10.5326/JAAHA-MS-7292>
22. Dharmshaktu, P., Tayal, V. & Kalra, B. S. (2012) Efficacy of antidepressants as analgesics: a review. *Journal of Clinical Pharmacology* 52, 6-17
23. Millis, D. (2021). Multimodal Pain Management for Canine Osteoarthritis. *Today's Veterinary Practice*. [https://todaysveterinarypractice.com/pain\\_management/multimodal-pain\\_management-for-canine-osteoarthritis/](https://todaysveterinarypractice.com/pain_management/multimodal-pain_management-for-canine-osteoarthritis/)
24. Cimavet.aemps.es. (n.d.). <https://cimavet.aemps.es/>
25. Calandre, E. P., Rico-Villademoros, F. & Slim, M. (2016) Alpha(2)delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. *Expert Review of Neurotherapeutics* 16, 1263-1277

26. Sirin, D. Y. & Karaarslan, N. (2018). Evaluation of the effects of pregabalin on chondrocyte proliferation and Chad, HIF-1 $\alpha$ , and COL2A1 gene expression. *Archives of Medical Science*, 14(6), 1340–1347.
27. Peck, C. (2018). The adverse effect profile of gabapentin in dogs A retrospective questionnaire study. Uppsala.
28. Erickson, A., Harbin, K., MacPherson, J., Rundle, K., & Overall, K. L. (2021). A review of pre-appointment medications to reduce fear and anxiety in dogs and cats at veterinary visits. *The Canadian Veterinary Journal*, 62(9), 952.
29. Di Cesare, F., Negro, V., Ravasio, G., Villa, R., Draghi, S., & Cagnardi, P. (2023). Gabapentin: Clinical use and pharmacokinetics in dogs, cats, and horses. *Animals*, 13(12), 2045.
30. Onakpoya, I. J. (2020) Paracetamol as first line for treatment of knee and hip osteoarthritis. *BMJ Evidence-Based Medicine* 25, 40
31. Pettitt, R. A. & German, A. J. (2015) Investigation and management of canine osteoarthritis. *In Practice* 37, 1-8
32. Perez Jimenez, T. E., Mealey, K. L., Grubb, T. L., et al. (2016) Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: species comparison and identification of responsible canine cytochrome P-450s (CYPs). *Drug Metabolism and Disposition* 44, 1963-1972
33. Miles, J., Bøjesen, J., Christensen, P., et al. (2020) Tramadol and gabapentin improve peak vertical force in osteoarthritic dogs already receiving non-steroidal anti-inflammatory drugs. *BSAVA Congress Proceedings 2020. British Small Animal Veterinary Association*
34. Kieves, N. R., Howard, J., Lerche, P., Lakritz, J., & Aarnes, T. K. (2020). Effectiveness of tapentadol hydrochloride for treatment of orthopedic pain in dogs: A pilot study. *The Canadian veterinary journal = La revue veterinaire canadienne*, 61(3), 289–293.
35. Gamble L-J, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, et al. ( 2018) Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. *Front Vet Sci* [Internet]. ;5. Disponible en: <http://dx.doi.org/10.3389/fvets.2018.00165>
36. Yu, C. H. J., & Rupasinghe, H. P. V. (2021). Cannabidiol-based natural health products for companion animals: Recent advances in the management of anxiety, pain, and inflammation. In *Research in Veterinary Science* (Vol. 140, pp. 38–46). Elsevier B.V. <https://doi.org/10.1016/j.rvsc.2021.08.001>
37. Brioschi, F. A., Di Cesare, F., Gioeni, D., Rabbogliatti, V., et al., (2020). Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: Effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. *Animals*, 10(9), 1–14. <https://doi.org/10.3390/ani10091505>
38. Mejia S, Duerr FM, Griffenhagen G, McGrath S. ( 2021) Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: A pilot study in dogs. *J*

Am Anim Hosp Assoc [Internet]. ;57(2):81–90. Disponible en:  
<http://dx.doi.org/10.5326/JAAHA-MS-7119>

39. Pérez, J. M. D., Rodríguez, J. M., & Sarmiento, J. A. F. (2022). Fármacos para la osteoartritis modificadores de la estructura ( DMOAD) y nutracéuticos. *Canis et Felis*, 176.
40. D’Altilio, M., Peal, A., Alvey, M., Simms, C., et al. (2007) Therapeutic efficacy and safety of undenatured type II collagen singly or in combination with glucosamine and chondroitin in arthritic dogs. *Toxicol Mech Methods*,17: 189–196
41. Huebner, K.D., Shrive, N.G., Frank, C.B., (2014). Dexamethasone inhibits inflammation and cartilage damage in a new model of post-traumatic osteoarthritis. *J Orthop Res*.32(4):566-72.
42. Boston, S. E., Moens, N. M., Kruth, S. A., et al. (2003) Endoscopic evaluation of the gastroduodenal mucosa to determine the safety of short-term concurrent administration of meloxicam and dexamethasone in healthy dogs. *American Journal of Veterinary Research* 64,1369-1375
43. Bogers SH. (2018). Cell-based therapies for joint disease in veterinary medicine: what we have learned and what we need to know. *Front Vet Sci*. 5:70. PMID: 29713634; PMCID: PMC5911772.
44. Domaniza, M., Trbolova, A., Hluchy, M., Cizkova, D. (2021). Mesenchymal stem cell-based treatment of osteoarthritis in dogs – a review. *SRDTJ Stem Cell Res Dev Ther*. 7(4):1–7.
45. Punzón, E., Salgüero, R., Totusaus, X., Mesa-Sánchez, C., Badiella, L., García-Castillo, M., & Pradera, A. (2022). Equine umbilical cord mesenchymal stem cells demonstrate safety and efficacy in the treatment of canine osteoarthritis: A randomized placebo-controlled trial. *Journal of the American Veterinary Medical Association*, 260(15), 1947–1955. <https://doi.org/10.2460/javma.22.06.0237>
46. Sharun, K., Muthu, S., Mankuzhy, P. D., Pawde, A. M., et al. (2022). Cell-free therapy for canine osteoarthritis: Current evidence and prospects. *Veterinary Quarterly*, 42(1), 224–230. <https://doi.org/10.1080/01652176.2022.2145620>
47. Alves, J. C., Santos, A. & Jorge, P. (2021a) Platelet-rich plasma therapy in dogs with bilateral hip osteoarthritis. *BMC Veterinary Research* 17, 207
48. Franklin, S. P., Garner, B. C. & Cook, J. L. (2015) Characteristics of canine plateletrich plasma prepared with five commercially available systems. *American Journal of Veterinary Research* 76, 822-827
49. Venator, K. P., Frye, C. W., Gamble, L. J., & Wakshlag, J. J. (2020). Assessment of a Single Intra-Articular Stifle Injection of Pure Platelet Rich Plasma on Symmetry Indices in Dogs with Unilateral or Bilateral Stifle Osteoarthritis from Long-Term Medically Managed Cranial Cruciate Ligament Disease. *Veterinary medicine (Auckland, N.Z.)*, 11, 31–38. <https://doi.org/10.2147/VMRR.S238598>

50. Kosiński, J., Jarecki, J., Przepiorka-Kosińska, J. & Ratajczak, M. (2020). Hyaluronic acid in orthopedics. *Wiadomości lekarskie*, 73(9 cz. 1), 1878–1881.
51. Lee, M. I., Kim, J. H., Kwak, H. H., Woo, H. M., Han, J. H., Yayon, A., Jung, Y. C., Cho, J. M., & Kang, B. J. (2019). A placebo-controlled study comparing the efficacy of intra-articular injections of hyaluronic acid and a novel hyaluronic acid-platelet-rich plasma conjugate in a canine model of osteoarthritis. *Journal of orthopaedic surgery and research*, 14(1), 314. <https://doi.org/10.1186/s13018-019-1352-1>
52. D'Adamo, S., Cetrullo, S., Panichi, V., Mariani, E., et al. (2020) Nutraceutical Activity in Osteoarthritis Biology: A Focus on the Nutrigenomic Role. *Cells*, 9, 1232
53. Fernández-Martín S, González-Cantalapiedra A, Muñoz F, García-González M, Permuy M, López-Peña M.(2021) Glucosamine and Chondroitin Sulfate: Is There Any Scientific Evidence for Their Effectiveness as Disease-Modifying Drugs in Knee Osteoarthritis Preclinical Studies. A Systematic Review from 2000 to 2021. *Animals (Basel)*, 29,11(6):1608.
54. Chen, J.S. & Hill, C.L. (2016). Supplementation with omega-3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2-year randomized controlled trial. *Osteoporos Int*. Vol.27 (5), 1897-905.
55. Wander RC, Hall JA, Gradin JL, Du SH, Jewell DE. ( 1997) The ratio of dietary (n=6) to (n=3) fatty acids influences immune system function, eicosanoid metabolism, lipid peroxidation, and vitamin E status in aged dogs: *J Nutr*, 127:1198-1205
56. Bhathal, A., Spryszak, M., Louizos, C. & Frankel, G. (2017). Glucosamine and chondroitin use in canines for osteoarthritis: A review. *Open Veterinary Journal*, 7(1), 36–49.
57. Jan Corbee, R. (2022). Review for “the efficacy of a nutritional supplement containing green-lipped mussel, curcumin and blackcurrant leaf extract in dogs and cats with osteoarthritis.” *VetMed Sci.* 2022;8:1025–1035. <https://doi.org/10.1002/vms3.779/v2/review2>
58. Johnson, K. A., Lee, A. H., & Swanson, K. S. (2020). Nutrition and nutraceuticals in the changing management of osteoarthritis for dogs and cats. *Journal of the American Veterinary Medical Association*, 256(12), 1335–1341. <https://doi.org/10.2460/javma.256.12.1335>
59. Reichling J, Schmökel H, Fitz J, Bucher S, Saller R. (2004) Dietary support with *Boswellia* resin in canine inflammatory joint and spinal disease. *Schweiz Arch Tierheilkd*. Feb;146(2):71-9. doi: 10.1024/0036-7281.146.2.71. PMID: 14994484
60. Musco N, Vassalotti G, Mastellone V, Cortese L, Della Rocca G, Molinari ML, Calabrò S, Tudisco R, Cutrignelli MI, Lombardi P. Effects of a nutritional supplement in dogs affected by osteoarthritis. *Vet Med Sci*. 2019 Aug;5(3):325-335. doi: 10.1002/vms3.182. Epub 2019 Jul 17. PMID: 31313893; PMCID: PMC6682793.